Active ingredientAlpelisibCat. No. P-A092-001CAS 1217486-61-7Family · Pharmaceutical analytical standards
Alpelisib
A selective inhibitor of phosphoinositide 3-kinase alpha (PI3Kα), approved in 2019 in the United States and in 2020 in Europe for advanced breast cancer with a mutation in the PIK3CA gene. This family brings together the active ingredient, labelled standards and nitrosamines.
Did you know?In 2022 the United States also approved it for PIK3CA-related overgrowth spectrum (PROS), rare conditions in which a mutation in the same gene makes parts of the body grow too much.
Go to the active ingredient →Active ingredientAlpelisibCat. No. P-A092-001CAS 1217486-61-7
Isotopically labelledAlpelisib-d3,15N2Cat. No. P-A092-003
NitrosamineN-Nitroso AlpelisibCat. No. P-A092-004No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.